A rapid and sensitive rp-hplc method for the quantitative analysis of empagliflozin in bulk and pharmaceutical dosage form

Abstract

Objective: The present study aims at developing an accurate precise, rapid and sensitive Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) method for assessing Empagliflozin in bulk drug and in the pharmaceutical dosage form. Methods: The proposed method employs a Reverse Phase Shim Pack C18 column (250 mm × 4.6 mm id; 5 µm) using a mobile phase comprising of acetonitrile and water in the ratio of 60:40 v/v flushed at a flow rate of 1 ml/min. The eluents were monitored at 223 nm. Results: Empagliflozin was eluted at a retention time of 5.417 min and established a co-relation co-efficient (R2>0.999) over a concentration ranging from 0.0495-100µg/ml. Percentage recovery was obtained between 98-102% which indicated that the method is accurate. The Limit of Detection (LOD) and Limit of Quantitation (LOQ) were found at 0.0125µg/ml and 0.0495µg/ml, respectively. Conclusion: An RP-HPLC method which was relatively simple, accurate, rapid and precise was developed and its validation was performed for the quantitative analysis of empagliflozin in bulk and tablet dosage form (10 and 25 mg) in accordance to International Conference of Harmonization (ICH) Q2 (R1) guidelines. The proposed method may aid in routinely analyzing empagliflozin in pharmaceuticals.

Full text

A RAPID AND SENSITIVE RP-HPLC METHOD FOR THE QUANTITATIVE ANALYSIS OF
EMPAGLIFLOZIN IN BULK AND PHARMACEUTICAL DOSAGE FORM
Original Article
MADHURIMA BASAK, SANTHOSH REDDY GOURU, ANIMESH BERA, KRISHNA VENI NAGAPPAN*
a
Received: 29 Mar 2019, Revised and Accepted: 06 Jun 2019
Department of Pharmaceutical Analysis, JSS College of Pharmacy, Ooty, (A Constituent College-JSS Academy of Higher Education and
Research), Tamilnadu, India
Email: krisath@gmail.com
ABSTRACT
Objective: The present study aims at developing an accurate precise, rapid and sensitive Reverse Phase High-Performance Liquid Chromatography
(RP-HPLC) method for assessing Empagliflozin in bulk drug and in the pharmaceutical dosage form.
Methods: The proposed method employs a Reverse Phase Shim Pack C18
Results: Empagliflozin was eluted at a retention time of 5.417 min and established a co-relation co-efficient (R
column (250 mm × 4.6 mm id; 5 µm) using a mobile phase comprising of
acetonitrile and water in the ratio of 60:40 v/v flushed at a flow rate of 1 ml/min. The eluents were monitored at 223 nm.
2
Conclusion: An RP-HPLC method which was relatively simple, accurate, rapid and precise was developed and its validation was performed for the
quantitative analysis of empagliflozin in bulk and tablet dosage form (10 and 25 mg) in accordance to International Conference of Harmonization
(ICH) Q2 (R
>0.999) over a concentration
ranging from 0.0495-100µg/ml. Percentage recovery was obtained between 98-102% which indicated that the method is accurate. The Limit of
Detection (LOD) and Limit of Quantitation (LOQ) were found at 0.0125µg/ml and 0.0495µg/ml, respectively.
1
Keywords: Empagliflozin, RP-HPLC, Method Optimization, Method Validation
) guidelines. The proposed method may aid in routinely analyzing empagliflozin in pharmaceuticals.
© 2019 The Autho rs. Published by Innov are Academic Sciences Pvt Ltd. This is an open acc ess article under the CC BY license (http://cr eativecommons.org /licenses/by/4.0/)
DOI: http://dx.doi.org/10.22 159/ijap.2019v11i5.33281
INTRODUCTION
Type 2 Diabetes mellitus (T2DM) is a popular chronic metabolic
disorder caused by insulin insensitivity and decreased level of insulin
secretion. In 2017, International diabetes federation reported that the
prevalence of diabetes is 9.4% of the population with 90-95% cause
being T2DM [1]. Diabetes mellitus is accompanied with risks of
cardiovascular morbidity and mortality, The tight “glucocentric”
approach to the treatment of diabetes by the precedent antidiabetic
drugs delivered a setback. This augmented regimen was aborted when it
became apparent that it raises the risk of cardiovascular (CV) mortality
(as stated by ACCORD-Action to Control CV Risk in diabetes in 2007) [2].
An appropriate antidiabetic should not only be concerned with rectifying
metabolic dysfunction but also to protect the cardiovascular system
from the effects of epigenetic changes resulting from hyperglycemia.
Fig. 1: Chemical structure of Empagliflozin
Empagliflozin is (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-
yloxy] phenyl} methyl) phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
having a molecular formula of C23 H27 ClO 7
An extensive study of methods prevailing in regard to the assessment of
empagliflozin independently and in combination of other antidiabetic
drugs has divulged a number of analytical and spectral techniques [7-8].
and molecular weight of
450.912 g/mol is a orally administered sodium-glucose co-transporter II
inhibitor (SGLT-2) (fig. 1). Renal tubular sodium-glucose co-transporter
receptors are engaged with elevated reabsorption of tubular glucose [3].
High reabsorption of sodium in the proximal tubule causes decreased
shipment of sodium to the macula densa resulting in vasodilation of the
afferent arteriole with simultaneous constriction of the efferent arteriole
eliciting inter glomerular hypertension [4]. Empagliflozin inhibits the
SGLT-2 inhibitor receptors thereby eradicate these effects and
concurrently diminishing both preload (by Diuresis) and afterload (by
decreasing arteriole stiffness and blood pressure) resulting in
considerable reduction in CV mortality [5]. A review examines the
pharmacokinetic characteristics of empagliflozin in healthy individuals,
and in patients with T2DM treated with empagliflozin monotherapy [6].
Empagliflozin counters diabetes by inhibiting about 90% of glucose into
the blood and excretes it through urine.
Madana et al. (2017) divulged that a mobile phase with a concoction
of phosphate buffer at pH 3 and methanol in the ratio 30:70 v/v
when flushed on a dikma C 18 column (50 x 2.1 mm,1.8 µm) an RP-
HPLC method was developed for estimation of empagliflozin in the
presence of its degradants [9]. Sushil et al. (2017) have reported an
RP-HPLC method for the quantification of empagliflozin using an
Intersil C8 (250 x 4.6 mm x 5 µm) column and a mobile phase
comprising of 0.1% orthophosphoric acid and acetonitrile in the
ratio 50:50 v/v in gradient elution [10]. Ghadir et al. (2018)
publicized a method for evaluation of empagliflozin in routine
analysis which was materialized through acetonitrile: 0.05 M
Potassium Dihydrogen phosphate buffer at pH 4 in the ratio of 65:35
v/v in isocratic mode [11]. Sharmila et al. (2018) proclaimed that
determination of empagliflozin in bulk and pharmaceutical dosage
form was done through discovery C18
MATERIALS AND METHODS
column (250 x 4.6 mm, 5 µm)
in association with a buffer and acetonitrile in the proportion of
68:32 [12]. Literature pertaining to development of a stability-
indicating RP-HPLC method of empagliflozin revealed that most of
the researchers used buffers like acetate, potassium dihydrogen
salts or acids like orthophosphoric acid to adjust the pH for
appropriate separation of the analytes. So, this article targets to
develop and validate a rather simpler, rapid, precise, accurate,
highly sensitive and selective RP-HPLC method that can be used for
routine analysis and control of quality in pharmaceutical industries.
Chemicals
HPLC grade acetonitrile was acquired from merck industries
(Mumbai, India). HPLC grade water was generated, employing a Mili
Q water system (Bangalore, India). The reference standard of
empagliflozin was received as a gift sample from mylan Industries
I
In
nt
te
er
rn
na
at
ti
io
on
na
al
l
J
Jo
ou
ur
rn
na
al
l
o
of
f
A
Ap
pp
pl
li
ie
ed
d
P
Ph
ha
ar
rm
ma
ac
ce
eu
ut
ti
ic
cs
s
ISSN- 0975-7058 Vol 11, Issue 5, 2019

Nagappan et al.
Int J App Pharm, Vol 11, Issue 5, 2019, 60-65
61
(Hyderabad, India). The marketed formulation was purchased from
a local pharmacy, The Nilgiris.
Instrumentation
Experiments pertaining to HPLC were exercised on shimadzu LC-
2010A autosampler (Shimadzu Corporation, Kryto, Japan). The
system was equipped with a quaternary low pressure mixing pump
(LC-2010A) and an UV-detector (Shimadzu SPD-20A), a shim pack
solar RP-C 18
Selection of wavelength
column (250 x 4.6 mm; 5 µm), an autosampler with 20
µl aliquots sample loop volume was used for the chromatographic
analysis. The software, Class VP data station was employed for data
collection and analysis. A shimadzu 1700(E) spectrometer was
engaged for recording the UV spectra.
A standard solution containing 1 mg/ml empagliflozin in acetonitrile
was prepared. From the stock solution. A secondary solution was
prepared by dissolving 1 ml of the standard solution in the mobile
phase. The standard solution was scanned at wavelengths ranging
from 200-400 nm. Empagliflozin exhibited maximum absorbance at
223 nm (fig. 2). Thus it was stipulated as the λmax for surveilling the
chromatographic eluents.
Fig. 2: UV spectra of Empagliflozin
Standard and sample preparations
10 mg of empagliflozin API was dissolved in acetonitrile HPLC grade
in a 10 ml volumetric flask (1 mg/ml) for preparing the primary
standard. From this standard stock solution a series of dilution viz.;
100µg/ml,10µg/ml and 1µg/ml were prepared in the mobile phase,
which then served as 100% target concentration.
Assay of the marketed formulation
10 film-coated tablets of marketed empagliflozin (10 mg and 25 mg)
were separately weighed and finely powdered in a mortar and pestle
and a quantity equivalent to the average weight of the formulation was
transferred to two 100 ml volumetric flasks and dissolved in about 60
ml of mobile phase and sonicated for about 10 min. These solutions
were then filtered through whattman filter paper and the volume was
adjusted to 100 ml with mobile phase (solution A). 1 ml of solution A
was transferred to a 10 ml volumetric flask and the volume was
adjusted with mobile phase to obtain a working standard having a
concentration of 10µg/ml and 25µg/ml respectively. These solutions
were analysed in triplicate using optimized chromatographic
conditions. The chromatograms were recorded and the amount of the
drug present was assessed, standard deviation and the %RSD
(Relative Standard Deviation) was calculated and reported.
Linearity and range
Linear proportionality of the acquired response to that of the
analyte concentration specifies the linearity of the said analytical
method. Concentrations ranging between 0.0495-25µg/ml were
assessed for determining the linearity of the proposed method.
Preparation of the working standards was done by diluting the
primary stock solution bearing the concentration of 1 mg/ml in
mobile phase. These range of concentrations were injected in
threefold under chromatographic conditions that have been
optimized and the respective chromatograms were documented.
The linearity was established based on the co-relation co-efficient
obtained by plotting a graph with concentration in µg/ml at the x-
axis and peak area of empagliflozin at the y-axis.
Precision and accuracy studies
Intraday and interday studies assess the precision of the designed
method. Six independent injections of three different concentrations
i.e. 1, 4, 16 µg/ml Low-Quality Control (LQC), Medium Quality
Control (MQC) and High-Quality Control (HQC level) were utilized in
the study of the proposed method. Intraday precision, as well as
repeatability, was examined by analyzing the samples on the same
day and the interday precision was done by analysing these same
samples (as used in intraday study) on three different days.
Calculations for mean and %RSD were carried out by using the
values obtained from interday and intraday studies.
Recovery studies elicit the accuracy of the method. The accuracy of
the method was assessed by the standard addition method, i.e.
analysis of the sample solution spiked with the known concentration
of the sample prepared from formulation under optimized
chromatographic condition. The recovery results acquired from the
3 different levels (1, 4, 16 µg/ml) of concentrations made way for
the calculations of %mean recovery, standard deviation, and
%relative standard deviation and were reported.
LOD and LOQ
Sensitivity of a method determines how capable is the method for
detecting the lowest possible concentration of analyte without any
noise. This is assessed by the parameter of LOD and LOQ. Limit of
Detection (LOD) is the smallest concentration of the analyte that can
be detected by the developed method which evokes a computable
response (signal to noise ratio 3) where Limit of quantification(LOQ)
is the least concentration of the analyte which generates a response
that can be precisely quantified (Signal to noise ratio 10).
LOD and LOQ can be calculated by the formula:
 =
3.3 ∗ 

 =
10 ∗ 

Where σ = Standard deviation of the response; S = Slope of the
deviation curve.
Robustness
The parameter of ruggedness and robustness of the developed
method was scaled by bringing about slight changes in the stated
experimental conditions like minute deviations in analyte

Nagappan et al.
Int J App Pharm, Vol 11, Issue 5, 2019, 60-65
62
concentrations, source of reagent, various brands of columns and
marginal variability in ratio of the mobile phase, flow of eluents etc.
System suitability
System suitability parameters play a key role in development and
validation of an analytical method ensuring the optimal performance
of the system. Chromatographic parameters viz; number of
theoretical plates (N), retention time (Rt), Resolution(Rs
RESULTS
) and
asymmetric peak factor (A) were scanned on injecting 6 replicates of
the standard empagliflozin at a concentration of 10 µg/ml.
Method development
The proposed method was designed by optimizing the
chromatographic conditions by pertaining to various trial runs
altering the mobile phase composition, the ratio of the mobile phase,
pH, column, column length to attain symmetrical analyte peak at a
sufficiently short run time. Acetonitrile was used as an organic
modifier in the mobile phase. Initially, various ratios of acetonitrile
and water were employed as the mobile phase for separations,
exhibited peak asymmetry.
Finally, asymmetric analyte peak with an acceptable short run time
was achieved employing acetonitrile and water in a ratio of 40:60
v/v at a flow rate of 1 ml/min, with a Shim pack C18
Empagliflozin was eluted at 5.45 min. The mobile phase was
prepared by filtering through a 0.45µ PTFE (Poly Tetra fluoro
ethylene) membrane filter before incorporating in the HPLC system.
Class VP data station recorded and processed the chromatograms.
(250 mm X 4.6
mm, 5 µm) being utilized as the stationary phase and the eluents
were monitored at a wavelength of 223 nm.
Method validation
The RP-HPLC method that was developed was targeted for
quantifying empagliflozin and validation of the designed method
was carried out in accordance to the ICH guidelines for the
parameters namely linearity, precision, specificity, accuracy,
robustness, ruggedness, detection limit and quantitation limit [13].
Specificity/selectivity
The specificity of the method was illustrated by injecting the
diluents, standard solution of empagliflozin and the sample solution
extracted from the tablet formulation for any co-eluting peaks
within the retention time of the drug (5.45±0.05 min). No co-eluting
peak was observed, a sharp and symmetric peak shape
demonstrated the specificity of the method. The chromatograms of
the sample solutions and standards are depicted in fig. 3 and 4.
Fig. 3: Typical chromatogram of the standard solution (Empagliflozin–10 µg/ml)
Fig. 4: Typical chromatogram of the sample solution extracted from tablet dosage form (10 mg tablet)

Nagappan et al.
Int J App Pharm, Vol 11, Issue 5, 2019, 60-65
63
Accuracy and precision
The accuracy of the devised method was demonstrated as the
percentage recovery at the concentrations of 1, 4, 16µg/ml with the
aid of the standard addition method. The threefold analysis was
excercised for each level and the mean % recovery was calculated.
The accuracy of the developed method was found to be ranging
between 98%-102% (table 1). Assay of the marketed tablet
formulation was also performed and reported. The obtained result is
on par with label claim and has been enumerated in table 2. The
intraday and inter-day precision studies carried out showed a %
RSD of<2% indicating the precision of the method (table 3).
Table 1: Accuracy studies of Empagliflozin
S. No.
Actual concentration (µg/ml)
Recovered concentration
*
Percentage recovered
(µg/ml)±SD; %RSD
1
1
0.98±0.005;0.58
98%
2
4
3.96±0.015; 0.38
99%
3
16
15.97±0.015;0.09
99.8%
*mean of 03 determinations
Table 2: Assay of marketed formulations
S. No.
Sample
Label claim
Amount present
*
(mg/vial)±SD; %RSD
1
Formulation–I
10 mg
9.83±0.040;0.410
2
Formulation–II
25 mg
24.83±0.051316;0.206
*mean of 03 determinations
Table 3: Precision studies of Empagliflozin
S. No.
Concentration (µg/ml)
Intraday mean*±SD; %RSD (n=6)
Interday mean*±SD; %RSD (n=6)
1
1 (LQC)
0.9917±0.0090; 0.915
0.9875±0.0077; 0.787
2
4(MQC)
3.9209±0.0031;0.079
3.9701±0.0723; 1.822
3
16(HQC)
15.9556±0.0335; 0.210
15.9000±0.0713; 0.448
*mean of 03 determinations, (LQC–Low-Quality control; MQC–Middle-Quality Control; HQC–High-Quality Control samples)
Linearity
Six different concentrations against corresponding peaks were
plotted for developing the calibration curve. The graph showed
excellent correlation between the concentrations and peak area
when observed within the range of (0.0495-25µg/ml) for
empagliflozin. The co-relation co-efficient for empagliflozin was ≥
0.998, the slope and the intercept were depicted at 91860 and 3837
respectively. The graph depicting linearity of the method is
represented in fig. 5.
Table 4: Linearity
Conc of the drug (µg/ml) Peak area*
0.0495
4937
0.099
9734.5
0.1988
19408.5
0.39
39239.5
1.7812
84657.5
1.56
153479
3.125
301288
6.25
593940.5
12.5
1149073.5
25
2286462.5
Regression Co-efficient
Y=91860x-3837
C0rrelation Co-efficient
0.998
*
mean of six determinations
Fig. 5: Linearity plot of empagliflozin

Nagappan et al.
Int J App Pharm, Vol 11, Issue 5, 2019, 60-65
64
Detection limit and quantification limit
The detection and quantification limit illustrates the sensitivity of the
devised method. The LOD and LOQ were found to be 0.0125µg/ml and
0.0495µg/ml, respectively indicating the sensitivity of the method.
These results have been tabulated in table 5.
System suitability
Six replicates of the standard at working concentrate were injected to
observe changes in separation, retention time and asymmetry of the
peaks and validate the system suitability parameters. The system
suitability was found to be within limits and are summarized in table 6.
Table 6: System Suitability parameters
S. No.
Parameters
Empagliflozin
1.
Retention time (min)
5.417
2.
Theoretical plates (N)
2014
3
Tailing Factor
0.67
4
Asymmetry factor (A)
1.0
5
Regression coefficient (R2
0.998
)
6
Regression equation
Y=91860x-3837
7
Linearity and Range
0.0495-25μg/ml
8
Detection Limit (LOD)
0.0125 µg/ml
9
Quantification Limit (LOQ)
0.0495 µg/ml
Table 7: Robustness results
S. No.
Parameters
Retention time (min)
1.
Mobile phase ratio
(Acetonitrile: Water)
58:32
5.25±0.2
60:40
5.45±0.2
62:38
5.58±0.2
2.
Temperature ( °C)
17
5.42±0.2
22
5.45±0.2
27
5.43±0.2
3.
Flow rate
(ml/min)
0.8
5.40±0.2
1
5.45±0.2
1.2
5.48±0.2
Robustness
A slight alteration in the flow rate (± 0.2 ml/min), column temperature
(± 5°C) and organic phase composition by ±2 % variations exhibited no
significant changes in the chromatographic parameters corroborating
the developed method to be robust (table 7).
DISCUSSION
A constructive attempt has been made for this RP-HPLC method to
achieve reliable quantification of empagliflozin and its stressed
degradants. Optimization has been done after trials executed
through variable columns and mobile phases for attaining a cost-
effective and acclimatized conditions. The design of a method
depends upon the nature of the sample (ionic or ionizable,
hydrophobic or hydrophilic) and its degree of solubility. Since
empagliflozin is found to be readily soluble in polar solvents,
therefore RP-HPLC method was deemed to be appropriate for its
separation as reversed-phase chromatography. It is a technique
using alkyl chains covalently bonded to the stationary phase
particles in order to create a hydrophobic stationary phase, which
has a stronger affinity for hydrophobic or less polar compounds.
Reversed-phase chromatography employs a polar (aqueous) mobile
phase. As a result, hydrophobic molecules in the polar mobile phase
tend to adsorb to the hydrophobic stationary phase, and
hydrophilic molecules in the mobile phase will pass through the
column and are eluted first. The developed method has achieved
optimum system suitability parameters and possess a simple mobile
phase of isocratic mode where other reported methods are with
various buffers [6][8][14], temperature [14] and pH [6] imparted
conditions, current method is sensitive enough till 0.0125µg/ml as
LOD, 0.04951485µg/ml as LOQ and found to be in range up to
25µg/ml (table 4). Method got established with reliable system
suitability parameters. Validation for the method was performed as
per ICH guidelines Q2R1, Accuracy was achieved using tablet
formulations with two different label claims (table 1) and precision
was performed in intraday as well as interday for the LQC, MQC and
HQC concentrations with three determinations each have attained
%RSD values in limits (table 3). Method claims to be robust from
findings through varying conditions of selected parameters.
CONCLUSION
A RP-HPLC method that has been made rapid, simple, accurate,
precise and sensitive was designed and developed for empagliflozin
and the developed method was validated as per ICH guidelines. The
drug showed good linearity over concentrations ranging from
0.0495 to 25µg/ml. Recovery studies that were carried out
expressed the accuracy of the method. The mean recovery of the
validated method ranged between 98-102%.
ACKNOWLEDGEMENT
The authors are immensely gratified to Mylan laboratory,
Hyderabad, India for the gift sample of Empagliflozin (API).
AUTHORS CONTRIBUTIONS
All the author have contributed equally
CONFLICTS OF INTERESTS
Declared none
REFERENCES
1. https://diabetesatlas. org/resources/2017-atlas.html. [Last
accessed on 12 Mar 2019]
2. Tabish A Syed. Is diabetes becoming the biggest epidemic of
twenty-first century? Int J Health Sci 2007;1:8-5.
3. Scheen JA. Pharmacokinetic and pharmacodynamic profile of
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor.
Clin Pharmacokinet 2014;53:225-13.
4. Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the
treatment of type 2 diabetes: evidence to date. Drug Des Dev
Ther 2015;9:5803-793.
5. Raut SM, Maheswari A. Empagliflozin: novel antidiabetic and
pro-cardiac drug. Indian J Anaesth 2017;61:440-1.
6. Nermeen A. Review on the pharmacokinetics of empagliflozin,
an inhibitor of the sodium-glucose cotransporter-2. Asian J
Pharm Clin Res 2017;10:50-6.
7. Geetha SP, Lakshmana RK, Prasad KRS, Suresh BK.
Development and validation of stability-indicating reversed

Nagappan et al.
Int J App Pharm, Vol 11, Issue 5, 2019, 60-65
65
phase high-pressure liquid chromatography method for
simultaneous estimation of metformin and empagliflozin in
bulk and tablet dosage form. Asian J Pharm Clin Res
2016;9:126-35.
8. Padmaja N, Veerabhadram G. Method development and
validation of RP-HPLC for the estimation of empagliflozin in
API. Int J Pharm Sci Res 2016;7:727-4.
9. Madana Gopal N, Sridhar C. A validated the stability-indicating
ultra-performance liquid chromatographic method for
simultaneous determination of metformin hydrochloride and
empagliflozin in bulk drug and tablet dosage form. Int J Appl
Pharm 2017;9:45-50.
10. H Jaiswal Sushil, Katariyal MV, Katariyal V, R Katariya, GS
Karva, Koshe Kishor. Validated stability Indicating RP-HPLC
method for determination of process-related impurities in
Empagliflozin drug substances. World J Pharm Res
2017;6:1037-27.
11. Khalil A Ghadir. Salama Ismail, Gomaa S Mohammed, Helal A
Mohammad. Validated PR-HPLC method for simultaneous
determination of canagliflozin, dapagliflozin, empagliflozin, and
metformin. IJPCBS 2018;8:13-1.
12. Donepudi Sharmila, Achanta Suneeta. Validated HPLC-UV
method for simultaneous estimation of Linagliptin and
empagliflozin in Human plasma. Int J Appl Pharm 2018;10:56-61.
13. International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
use. Validation of Analytical Procedures: Text and Methodology
ICH Q2 (R1); 2005.
14. Geetha SA, Rajitha G, Ramya YY, Uma P. Analytical method
development and validation of new stability-indicating
reverse-phase high-performance liquid chromatography
method for simultaneous estimation of metformin
hydrochloride and empagliflozin in tablet dosage form. Asian J
Pharm Clin Res 2019;12:241-4.